This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Butler, L. M. Articles by Tilley, W. D. Search for Related Content PubMed PubMed Citation Articles by Butler, L. M. Articles by Tilley, W. D.

Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant

Dame Roma Mitchell Cancer Research Laboratories (L.M.B., P.J.N., G.B., C.S.Y.C., C.R., K.S., M.L., A.O., M.Y., M.P.B., W.D.T.), Department of Medicine, The University of Adelaide and Hanson Institute, and School of Molecular and Biomedical Science (M.M.C.), the University of Adelaide, Adelaide, South Australia 5000, Australia

Address all correspondence and requests for reprints to: Lisa M. Butler, Dame Roma Mitchell Cancer Research Laboratories, The University of Adelaide, Hanson Institute, P.O. Box 14, Rundle Mall, Adelaide, South Australia 5000, Australia. E-mail: lisa.butler{at}imvs.sa.gov.au.

There is increasing evidence that sensitization of the androgen receptor (AR) signaling pathway contributes to the failure of androgen ablation therapy for prostate cancer, and that direct targeting of the AR may be a useful therapeutic approach. To better understand how AR function could be abrogated in prostate cancer cells, we have developed a series of putative dominant-negative variants of the human AR, containing deletions or mutations in activation functions AF-1, AF-5, and/or AF-2. One construct, AR inhibitor (ARi)-410, containing a deletion of AF-1 and part of AF-5 of the AR, had no intrinsic transactivation activity but inhibited wild-type AR (wtAR) in a ligand-dependent manner by at least 95% when transfected at a 4:1 molar ratio. ARi-410 was an equally potent inhibitor of gain-of-function AR variants. Ectopic expression of ARi-410 inhibited the proliferation of AR-positive LNCaP cells, but not AR-negative PC-3 cells. Whereas ARi-410 also marginally inhibited progesterone receptor activity, this was far less pronounced than the effect on AR (50% vs. 95% maximal inhibition, respectively), and there was no inhibition of either vitamin D or estrogen receptor activity. In the presence of ligand, ARi-410 interacted with wtAR, and both receptors translocated into the nucleus. Whereas the amino-carboxy terminal interaction was not necessary for optimal dominant-negative activity, disruption of dimerization through the ligand binding domain reduced the efficacy of ARi-410. In addition, although inhibition of AR function by ARi-410 was not dependent on DNA binding, the DNA binding domain was required for dominant-negative activity. Taken together, our results suggest that interaction between ARi-410 and the endogenous AR in prostate cancer cells, potentially through the DNA binding and ligand binding domains, results in a functionally significant reduction in AR signaling and AR-dependent cell growth.

NURSA Molecule Pages Link:

Nuclear Receptors:   VDR  |  AR

Ligands:   Calcitriol  |  Dihydrotestosterone

This article has been cited by other articles:

				A. A. Peters, G. Buchanan, C. Ricciardelli, T. Bianco-Miotto, M. M. Centenera, J. M. Harris, S. Jindal, D. Segara, L. Jia, N. L. Moore, et al. Androgen Receptor Inhibits Estrogen Receptor-{alpha} Activity and Is Prognostic in Breast Cancer Cancer Res., August 1, 2009; 69(15): 6131 - 6140. [Abstract] [Full Text] [PDF]

				E. F. Need, H. I. Scher, A. A. Peters, N. L. Moore, A. Cheong, C. J. Ryan, G. A. Wittert, V. R. Marshall, W. D. Tilley, and G. Buchanan A Novel Androgen Receptor Amino Terminal Region Reveals Two Classes of Amino/Carboxyl Interaction-Deficient Variants with Divergent Capacity to Activate Responsive Sites in Chromatin Endocrinology, June 1, 2009; 150(6): 2674 - 2682. [Abstract] [Full Text] [PDF]

				M. M. Centenera, J. M. Harris, W. D. Tilley, and L. M. Butler Minireview: The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling Mol. Endocrinol., November 1, 2008; 22(11): 2373 - 2382. [Abstract] [Full Text] [PDF]